Psychiatric News (11/16) reports, “People who develop major depression following a COVID-19 infection appear to respond to treatment with selective serotonin reuptake inhibitors (SSRIs) within four weeks,” researchers concluded in a study that “included 60 adults (average age: 55 years) who developed a major depressive episode within six months following recovery from COVID-19 and were starting a new SSRI treatment; 26 were treated with sertraline, 18 with citalopram, 10 with paroxetine, four with fluvoxamine, and two with fluoxetine.” The findings were published online ahead of print in the upcoming January issue of the journal European Neuropsychopharmacology.
Related Links:
— “COVID-19 Survivors With Depression Respond to SSRIs Within 4 Weeks, Small Study Suggests, Psychiatric News, November 16, 2021